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AbstrACt
Objectives To evaluate the risk of major congenital 
anomaly associated with first-trimester exposure to insulin 
analogues compared with human insulin in offspring of 
women with pregestational diabetes.
Design and setting A population-based cohort of women 
with pregestational diabetes (n=1661) who delivered 
between 1996 and 2012 was established retrospectively 
from seven European regions covered bythe European 
Surveillance of Congenital Anomalies (EUROCAT) 
congenital anomaly registries.
Primary outcome measures The risk of non-
chromosomal major congenital anomaly in live births, fetal 
deaths and terminations for a fetal anomaly exposed to 
insulin analogues in the first trimester of pregnancy was 
compared with the risk in those exposed to human insulin 
only.
results During the first trimester, 870 fetuses (52.4%) 
were exposed to human insulin only, 397 fetuses (23.9%) 
to insulin analogues only and 394 fetuses (23.7%) to 
both human insulin and insulin analogues. The risk of 
major congenital anomaly in fetuses exposed to insulin 
analogues only was lower than those exposed to human 
insulin only; the relative risk adjusted for glycaemic 
control and region was 0.56 (95% CI 0.29 to 1.06). The 
significantly lower risk related to exposure of insulin 
analogues only was observed in congenital heart defects: 
adjusted relative risk 0.14 (95% CI 0.03 to 0.62).
Conclusions In this retrospective population-based cohort 
study across Europe, first-trimester exposure to insulin 
analogues did not increase the risk of major congenital 
anomaly compared with exposure to human insulin. A 
possible lower risk of congenital heart defects among 
fetuses exposed to insulin analogues only deserves further 
investigation.
IntrODuCtIOn
Women with pregestational diabetes mellitus 
(DM) (type 1 or type 2) have a higher risk 
of serious adverse pregnancy outcomes, 
including stillbirth, major congenital 
anomalies, and neonatal morbidity and 
mortality1–5 compared with women without 
diabetes. Isolated congenital heart defects 
account for one-third of all congenital 
anomalies in pregnancies with diabetes and 
a quarter in pregnancies without diabetes.6 
Although the mechanisms underlying the 
associations of DM with congenital anoma-
lies are not completely understood, there is 
evidence for a positive association between 
hyperglycaemia during embryogenesis and 
the risk for congenital anomalies.7 8 Precon-
ception care focusing on glycaemic control 
can improve pregnancy outcome and reduce 
strengths and limitations of this study
 ► A large retrospective population-based cohort of 
diabetic pregnancies from multiple centres that 
represent geographically distinct areas where 
patterns of diabetic treatment are different.
 ► The valid information on congenital anomaly was 
obtained by linkage to the EUROCAT database 
and by reclassification the cases with written text 
descriptions of a congenital anomaly based on 
EUROCAT subgroup definition.
 ► The data sources which were based on medical 
records and healthcare databases had incomplete 
data on haemoglobin A1c  (HbA1c) and pregnancy 
planning, but the association of congenital anomalies 
and insulin analogues was examined only among 
women who had had a HbA1c in the first trimester.
 ► The database does not contain information 
on lifestyle factors (eg, smoking, obesity, 
alcohol), preconception care (eg, screening and 
treatment of complications of diabetes, folic acid 
supplementation) which are also known to lower the 
risk of congenital anomaly.
 o
n
 18 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-014972 on 24 February 2018. Downloaded from 
2 Wang H, et al. BMJ Open 2018;8:e014972. doi:10.1136/bmjopen-2016-014972
Open Access 
the frequency of congenital anomalies in women with 
DM.9 
Clinical and experimental studies report that insulin 
analogues result in improved glycaemic control, more 
stable glycaemia, less glucose spikes, fewer hypoglycaemic 
episodes and improved patient satisfaction compared with 
the use of human insulin,10–12 which might have benefits 
for pregnant women. However, studies on exposure to 
insulin analogues during pregnancy are small and under-
powered to evaluate the risk of specific major congen-
ital anomalies.13 We conducted a study using a cohort 
of pregnancies with diabetes across Europe to evaluate 
the risk of major congenital anomalies associated with 
insulin analogue use in the first trimester of pregnancy 
compared with the use of human insulin.
MethODs
study population
A multicentre, retrospective cohort study was performed 
in seven regions in Europe, belonging to the EUROCAT 
network of population-based congenital anomalies regis-
tries, all obliged to value the same definitions, standards 
and procedures. Inclusion criteria were women with 
pregestational diabetes who had been referred to the 
hospitals in the region of study centre and delivered 
between 1996 and 2012. The study included live births, 
fetal deaths (spontaneous abortion, stillbirths) and termi-
nations for a fetal anomaly. Selection of study centres that 
captured pregnant women with DM for this study was on 
the basis of contacts within the EUROCAT network. The 
population of the study centre had to be covered by the 
EUROCAT network in order to evaluate the pregnancy 
outcome in terms of congenital anomaly. Each centre 
should include information on the key variables for evalu-
ating insulin analogues use in the first trimester. Informa-
tion on maternal drug exposure and other confounders 
was obtained from medical records. A total of 1877 fetuses 
of women with pregestational diabetes were enrolled 
in the study. We excluded 160 fetuses exposed to oral 
glucose-lowering medications in the first trimester and 56 
fetuses with unspecified maternal treatment of diabetes. 
The final cohort for the study included 1661 fetuses from 
1634 pregnancies.
Database of cohort with diabetes
Data on maternal demographics, type of diabetes, treat-
ment, that is, the name of the medication or complete 
seven-digit Anatomical Therapeutic Chemical classifica-
tion code, including the dispensing date and number of 
days of supply, duration of diabetes before conception, 
planned pregnancy, haemoglobin A1c (HbA1c) level and 
neonatal outcomes were collected from local medical 
records.
eurOCAt database
Details of the EUROCAT central database have been 
described previously.14 Congenital anomalies among 
live births, fetal deaths and terminations for a fetal 
anomaly are standardly recorded according to EUROCAT 
Guide 1.3.15 One syndrome and up to eight malforma-
tions are coded by International Classification of Diseases, 
Ninth Revision (ICD9) or 10th Revision (ICD10) codes. 
Minor anomalies, according to the EUROCAT classi-
fication system, are excluded. The follow-up period for 
inclusion of congenital anomaly in the EUROCAT varies 
among study regions: up to 1 week after birth in Mainz, 
up to 1 year after birth in Antwerp, Malta and Wales, 
up to 2 years after birth in Poznan, up to 5 years after 
birth in Funen and up to 16 years after birth in Northern 
Netherlands.
exposure definition
The relevant exposure period was defined from the date 
of the last menstrual period to week 13 of pregnancy (first 
trimester). All fetuses were classified according to first-tri-
mester maternal treatment of diabetes. The following 
three groups were included in the analysis: (1) fetuses 
exposed to human insulin only, (2) fetuses exposed to 
insulin analogue only and (3) fetuses exposed to both 
human insulin and insulin analogue. The reference 
group was fetuses exposed to human insulin only in the 
first trimester.
Outcome definitions
The primary outcome of interest was defined as the diag-
nosis of a major congenital anomaly in the infant/fetus, 
while the secondary outcome was a diagnosis of congenital 
heart defects. Written descriptions of congenital anoma-
lies based on medical records for live births, fetal deaths 
and terminations for a fetal anomaly at any gestational age 
were recorded in the database of cohort with diabetes. A 
two-stage process was used to identify and confirm fetuses 
with a major congenital anomalies. First, major congenital 
anomalies were identified by linking the database of cohort 
with diabetes to the EUROCAT central database. Second, 
unlinked cases with a written description of congenital 
anomalies were reviewed by a paediatrician (EG), blind 
to exposure status, to classify them into major versus 
minor congenital anomalies. All major congenital anom-
alies were grouped according to the EUROCAT classifica-
tion system.15 Fetuses with minor anomalies according to 
EUROCAT criteria were counted as not having a congen-
ital anomaly diagnosis. Chromosomal anomalies (n=5) 
were excluded from major congenital anomalies and 
congenital heart defects in the analysis of risk estimation 
and EUROCAT organ subgroup categorisation.
Preterm birth was defined as delivery before 37 weeks of 
gestation. We determined the percentile for birth weight 
for each neonate based on the gestational age using Dutch 
sex-specific standards.16 Large for gestational age (LGA) 
was defined as those above the 90th percentile weight by 
gestational age and sex. An adverse pregnancy outcome 
was defined as a major congenital anomaly or a fetal death, 
which included spontaneous abortion (gestational age <20 
weeks) and stillbirth (gestational age ≥20 weeks).
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statistical analyses
We compared the distributions of maternal and neonatal 
characteristics among the three exposure groups. 
One-way analysis of variance was used to compare the 
mean differences in maternal age at delivery, gestational 
age and birth weight for live births only between expo-
sure groups, and the Scheffe multiple comparison test was 
used for comparison with the reference group (human 
insulin only). Multinomial logistic regression was used to 
identify the differences in categorical variables between 
exposure groups. Associations between congenital anom-
alies/congenital heart defects and treatment of diabetes 
were estimated by calculating both crude and adjusted 
ORs and their 95% CIs using logistic regression models. 
ORs were adjusted for study centre (using a random-ef-
fect model) and HbA1c levels in the first trimester. HbA1c 
levels were collected from 3 months before pregnancy 
until delivery and a mean value was calculated for each 
trimester. The mean HbA1c level in the first trimester was 
classified into four categories: mean HbA1c ≤43 mmol/
mol (≤6.1%), mean HbA1c 44–53 mmol/mol (6.2%–
7.0%), mean HbA1c 54–67 mmol/mol (7.1%–8.3%) and 
mean HbA1c >67 mmol/mol (>8.3%) and unknown. 
Missing HbA1c levels in the first trimester (n=614) were 
excluded from the main analysis of risk estimation of 
major congenital anomalies/congenital heart defects, 
because the first-trimester level of HbA1c is essential 
when considering congenital abnormalities. A sensitivity 
analysis was conducted by including missing HbA1c as a 
separate group in the multivariate logistic model (online 
supplementary table). Analyses were performed using 
STATA V.13.
results
During the first trimester, 870 (52.4%) fetuses were 
exposed to human insulin only, 397 (23.9%) fetuses 
to insulin analogues only, 394 (23.7%) fetuses to both 
human insulin and insulin analogues. Of 397 fetuses 
exposed to insulin analogues only, 277 were exposed to 
short-acting insulin analogues only: 169 to insulin lispro, 
106 to insulin aspart and 1 to insulin glulisine. Of 120 
fetuses exposed to short-acting insulin analogues with 
long-acting insulin analogues, 93 were exposed to insulin 
glargine and 27 exposed to insulin detemir. The propor-
tion of insulin analogues only exposed fetuses increased 
from 3.2% in 1996–2002 to 20.8% in 2003–2007, and to 
39.3% in the period 2008–2012. We found regional differ-
ences in the proportion of exposure to insulin analogues 
only in the first trimester ranging from 3.8% in Malta to 
59.6% in Wales (table 1).
Compared with fetuses exposed to human insulin 
only in the first trimester, fetuses exposed to insulin 
analogues only were more common among women who 
planned their pregnancies (49.4% vs 23.9%, P<0.0001), 
with type 1 diabetes (95.5% vs 90.9%, P<0.004) and 
who had a longer duration of diabetes (64.2% vs 46.6%, 
P<0.0001). Overall, the mean HbA1c value in the first 
trimester was 55.5 mmol/mol (7.2%) (SD 16.1), Fetuses 
exposed to insulin analogue only in the first trimester 
were more likely to be in mean HbA1c 44–53 mmol/mol 
(6.2%–7.0%) group compared with those exposed to 
human insulin only (29.5% vs 13.8%, P<0.001) (table 2). 
Neonatal outcomes in terms of gender, LGA, death in the 
first week were similar among all groups. The propor-
tion of spontaneous abortion was 1.5% (n=6) among 
fetuses exposed to insulin analogues only, and 1.3% 
(n=5) among fetuses exposed to both insulin analogues 
and human insulin. These rates were significantly higher 
than fetuses exposed to human insulin only 0.1% (n=1) 
(table 2). Major congenital anomalies were observed in 
70 (8.0%) fetuses with human insulin only exposure, 15 
(3.8%) fetuses with insulin analogue only exposure and 19 
(4.8%) fetuses with human insulin and insulin analogue 
exposure. Fetuses from Northern Netherlands had the 
lowest rate of congenital anomaly overall (2.1%, 95% CI 
0.9% to 4.7%). The highest rate of congenital anomaly 
was seen in Antwerp (12.3%, 95% CI 7.3% to 19.8%).
A total of 1047 fetuses whose mother had a first-tri-
mester HbA1c were included in the analysis of the risk 
estimation of congenital anomalies/congenital heart 
defects. Compared with fetuses exposed to human insulin 
only, those exposed to insulin analogues only had a lower 
Table 1 Diabetic treatment in the first trimester by centre
Centre Birth year
Human insulin only, 
N=870
Insulin analogue only, 
N=397
Human insulin and insulin 
analogue, N=394
n % n % n %
Funen (N=206) 2000–2011 150 72.8 13 6.3 43 20.9
Northern Netherlands 
(N=270)
1999–2012 63 23.3 145 53.7 62 23.0
Malta (N=132) 1999–2011 127 96.2 5 3.8 0 0
Antwerp (N=99) 1997–2011 31 31.3 39 39.4 29 29.3
Mainz (N=204) 1996–2012 154 75.5 32 15.7 18 8.8
Wales (N=146) 1996–2012 54 37.0 87 59.6 5 3.4
Poznan (N=606) 1999–2012 292 48.2 77 12.7 237 39.1
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risk of major congenital anomaly (OR 0.54; 95% CI 0.29 
to 1.01), but not statistically significant. The risk of major 
congenital anomaly was significantly lower among those 
exposed to both human insulin and insulin analogues 
(OR 0.43; 95% CI 0.21 to 0.89). Mean HbA1c level in 
the first trimester was significantly associated with major 
congenital anomaly, with OR of 2.87 (95% CI 1.28 to 
6.42) for the HbA1c level above 67 mmol/mol (8.3%). 
Adjusting for the mean HbA1c in the first trimester and 
region did not change the risk estimates (table 3). The 
OR of congenital heart defects adjusted for region and 
HbA1c was 0.14 (95% CI 0.03 to 0.62) among fetuses 
with exposure to insulin analogue only, and 0.47 (95% 
CI 0.19 to 1.19) among those with exposure to both 
human insulin and insulin analogue, compared with 
the reference group (table 3). In the analysis of adverse 
outcomes (major congenital anomaly or fetal death), the 
point estimates did not show increased risks associated 
with exposure to insulin analogues (either alone or with 
human insulin), with an adjusted OR of 0.76 (95% CI 
0.44 to 1.33) for those exposed to insulin analogue only 
(table 3). In the sensitivity analysis, missing HbA1c levels 
in the first trimester (n=614) were included as a separate 
group in the multivariate model (online supplementary 
Table 2 Maternal and infant characteristics by treatment of diabetes in the first trimester†
Human insulin only, 
n (%)
Insulin analogue only, 
n (%)
Human insulin and 
insulin analogue, 
n (%)
N 870 397 394
Maternal characteristics
  Maternal age, mean (SD) 29.3±5.2 29.8±5.1 29.1±5.4
  Maternal age, >35 years 150 (17.2) 67 (16.9) 67 (17.0)
  Multiparous 515 (59.2) 216 (54.4) 211 (53.6)
  Planned pregnancy 208 (23.9) 196 (49.4)* 139 (35.3)
  Type 1 diabetes 791 (90.9) 379 (95.5) 359 (91.1)
  Duration of diabetes, >10 years 405 (46.6) 255 (64.2)* 188 (47.7)
  Chronic hypertension 42 (4.8) 25 (6.3) 15 (3.8)
  HbA1c first trimester
   ≤43 mmol/mol (≤6.1%) 109 (12.5) 54 (13.6) 66 (16.8)
   44–53 mmol/mol (6.2%–7.0%) 120 (13.8) 117 (29.5)* 66 (16.8)
   54–67 mmol/mol (7.1%–8.3%) 134 (15.4) 86 (21.7) 94 (23.9)
   >67 mmol/mol (>8.3%) 100 (11.8) 54 (13.6) 47 (11.9)
   Unknown 407 (46.8) 86 (21.7) 121 (30.7)
Infant characteristics
  Birth year
   ≤2002 363 (41.7) 13 (3.3) 25 (6.4)
   2003–2007 357 (41.0) 126 (31.7)* 121 (30.7)*
   2008–2012 150 (17.3) 258 (65.0)* 248 (62.9)*
  Fetal outcome
   Live birth 855 (98.3) 380 (95.7) 380 (96.4)
   Stillbirth 11 (1.3) 10 (2.5) 7 (1.8)
   Spontaneous abortion 1 (0.1) 6 (1.5)* 5 (1.3)*
   Termination 3 (0.3) 1 (0.3) 2 (0.5)
  Male sex 456 (52.4) 200 (50.4) 208 (52.8)
  Preterm delivery‡, <37 weeks 249 (29.2) 122 (32.7) 80 (21.1)*
  Large for gestation‡ 413 (48.7) 197 (53.4) 184 (48.6)
  Death in the first week‡ 6 (0.8) 1 (0.3) 0
The range of gestational age is 6–42 weeks.
*P<0.05.
†Reference group for comparison was fetuses exposed to human insulin only in the first trimester.
‡Among live birth.
HbA1c, haemoglobin A1c.
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table 1). The estimated ORs of major congenital anomaly 
overall or congenital heart defects with insulin analogue 
use were similar.
Planned pregnancy was associated with a lower risk of 
major congenital anomalies (OR 0.73, 95% CI 0.37 to 
1.46) and for congenital heart defects (OR 0.28, 95% CI 
0.20 to 1.58). Adjusting for other potential confounders 
(maternal age, planned pregnancy, diabetes type and year 
of delivery) did not significantly affect the estimated ORs 
of major congenital anomalies overall or congenital heart 
defects with insulin analogues use (data not shown).
Out of 311 fetuses exposed to insulin analogues only, 217 
(69.8%) were exposed to short-acting insulin analogues 
only and 94 (19.2%) were exposed to a combination of 
long-acting analogues with short-acting insulin analogues 
(table 4). When analyses were restricted to fetuses exposed 
to insulin analogues only, the significantly lower risk of 
major congenital anomalies/congenital heart defects was 
Table 4 ORs of non-chromosomal congenital anomalies by type of insulin analogues among fetuses exposed to insulin 
analogues only in the first trimester
N
Human insulin only
Insulin analogues only
Short-acting analogues 
only
Short-acting analogues and 
long-acting analogues
463 217 94
Major congenital anomaly
  n (%) 37 (8.0) 9 (4.2) 5 (5.3)
  Crude OR (95% CI) Reference 0.49 (0.23 to 1.04) 0.64 (0.24 to 1.68)
  Adjusted OR (95% CI)* Reference 0.57 (0.26 to 1.21) 0.54 (0.20 to 1.43)
Congenital heart defects
  n (%) 21 (4.5) 1 (0.5) 1 (1.1)
  Crude OR (95% CI) Reference 0.10 (0.01 to 0.72) 0.23 (0.03 to 1.70)
  Adjusted OR (95% CI)* Reference 0.12 (0.02 to 0.92) 0.18 (0.02 to 1.35)
Adverse outcomes†
  n (%) 42 (9.1) 15 (6.9) 6 (6.4)
  Crude OR (95% CI) Reference 0.74 (0.40 to 1.36) 0.68 (0.28 to 1.64)
  Adjusted OR (95% CI)* Reference 0.94 (0.45 to 1.98) 0.53 (0.21 to 1.36)
*Adjusted for centre as a random effect and adjusted for HbA1c value in the first trimester.
†Including major congenital anomaly or fetal deaths.
HbA1c, haemoglobin A1c.
Table 3 Relative risk of non-chromosomal congenital anomalies by treatment of diabetes in the first trimester
Human insulin only,
N=463
Insulin analogue only,
N=311
Human insulin and 
insulin analogue, N=273
Major congenital anomaly
  n (%) 37 (8.0) 14 (4.5) 10 (3.7)
  Crude OR (95% CI) Reference 0.54 (0.29 to 1.01) 0.43 (0.21 to 0.89)
  Adjusted OR (95% CI)* Reference 0.56 (0.29 to 1.06) 0.44 (0.22 to 0.91)
Congenital heart defects
  n (%) 21 (4.5) 2 (0.6) 6 (2.2)
  Crude OR (95% CI) Reference 0.14 (0.03 to 0.58) 0.46 (0.18 to 1.15)
  Adjusted OR (95% CI)* Reference 0.14 (0.03 to 0.62) 0.47 (0.19 to 1.19)
Adverse outcomes†
  n (%) 42 (9.1) 21 (6.8) 19 (7.0)
  Crude OR (95% CI) Reference 0.72 (0.42 to 1.24) 0.74 (0.42 to 1.31)
  Adjusted OR (95% CI)* Reference 0.76 (0.44 to 1.33) 0.77 (0.44 to 1.36)
*Adjusted for centre as a random effect and adjusted for HbA1c value in the first trimester.
†Including major congenital anomaly or fetal deaths.
 HbA1c, haemoglobin A1c. 
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seen in fetuses exposed to short-acting insulin analogue 
only (OR 0.12, 95% CI 0.02 to 0.92), although the point 
estimates were similar between exposure to short-acting 
insulin analogue only and short-acting and long-acting 
insulin analogues (table 4).
Table 5 describes the specific congenital anomalies 
diagnosed in all fetuses (n=1661). Congenital heart 
defects were the most frequent except in those exposed 
to insulin analogues only. Of the three congenital heart 
defects cases among insulin analogues only group, two 
were atrial septal defect (ASD) and one ventricular septal 
defect (VSD). Of the 35 fetuses with congenital heart 
defects exposed to human insulin only, two had severe 
congenital heart defects and the remaining 33 cases had 
septal defects or persistent ductus. There were no cases 
with caudal regression sequence.
DIsCussIOns
In this retrospective population-based cohort study, we 
found no increase in the risk of congenital anomalies in 
fetuses exposed to insulin analogues in the first trimester 
compared with those exposed to human insulin. Further-
more, a significantly lower risk of congenital heart defects 
was observed with exposure to insulin analogues.
In this cohort of pregnancies with diabetes, the rate 
of major congenital anomalies was 7.0% and about half 
of all major congenital anomalies were congenital heart 
defects. These rates are comparable with previous reports 
which found that the risk of congenital anomalies in the 
offspring of women with diabetes was between 4.6% and 
9.7%,2–4 17 a twofold to fivefold increase in risk compared 
with the general population in the study region.18 Our 
study confirms that unplanned pregnancy2 and elevated 
HbA1c levels in the first trimester are associated with a 
higher rate of congenital anomalies.19 20
In Europe, insulin analogues have been increasingly 
used during pregnancy in the last decade,21 and so, it is 
important to assess their safety. Studies have consistently 
showed no increased risk of congenital anomalies overall 
with the use of insulin analogues in pregnancy compared 
with the use of human insulin.22–25 Among a number of 
retrospective and observational studies on insulin lispro, 
the largest was a retrospective multinational study of 
533 pregnancies with pregestational diabetes,22 which 
reported a rate of major congenital anomalies of 5.4% 
(n=27, 95% CI 3.5% to 7.4%). An open-label randomised 
controlled trial found a 4.5% rate of congenital anomalies 
for insulin aspart among 322 women with type 1 diabetes, 
Table 5 Prevalence* of non-chromosomal congenital anomaly subgroups by treatment of diabetes in the first trimester
Human insulin only
N=870
Insulin analogues only
N=397
Human insulin and 
insulin analogue 
N=394
EUROCAT subgroups n (per 1000) n (per 1000) n (per 1000)
Nervous system 11 (12.6) 2 (5.0) 2 (5.1)
Ear, face and neck 1 (1.1) 0 0
Congenital heart defects 35 (40.2) 3 (7.6) 14 (35.5)
  Severe congenital heart defects 2 (2.3) 0 4 (10.2)
  Transposition of great vessels 0 0 2 (5.1)
  Single ventricle 1 (1.1) 0 0
  Ventricular septal defect 20 (23.0) 1 (2.5) 9 (22.8)
  Atrial septal defect 12 (13.8) 2 (5.0) 2 (5.1)
  Tetralogy of Fallot 0 0 1 (2.5)
  PDA as only congenital heart defects in term 
infants (GA +37 weeks)
1 (1.1) 0 1 (2.5)
Respiratory 1 (1.1) 1 (2.5) 1 (2.5)
Orofacial clefts 1 (1.1) 2 (5.0) 0
Digestive system 5 (5.7) 0 2 (5.1)
Urinary 10 (11.5) 3 (7.6) 1 (2.5)
Genital 3 (3.4) 2 (5.0) 2 (5.1)
Limb 9 (10.3) 4 (10.1) 1 (2.5)
Other anomalies/syndromes 4† (4.6) 0 1‡ (2.5)
*One fetus can be counted in more than one subgroup if it has multiple malformations, but only once in total.
†Including craniosynostosis (n=2), teratogenic syndromes with malformations (n=1), genetic syndromes+microdeletions (n=1).
‡Situs inversus (n=1).
GA, gestational age; PDA, patent ductus arteriosus.
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comparable to a 6.6% rate for human insulin.23 Most 
studies exploring the use of insulin glargine in pregnant 
women with diabetes are small, retrospective and without 
a reference group. A meta-analysis of eight studies on the 
use of insulin glargine in pregnancy showed a similar rate 
of congenital anomalies (8.1%) compared with the use 
of neutral protamine Hagedorn (NPH) (7.7%) (OR 0.97, 
95% CI 0.47 to 1.99).25 A multinational randomised 
control trial showed that the frequencies of congenital 
anomaly among insulin detemir or NPH were similar 
(insulin detemir: n=8/142, 5.6%; NPH: n=8/145, 5.5%).24
Our findings confirm and extend these observations. 
The risk of congenital anomalies was lower in fetuses 
exposed to insulin analogues, in particular short-acting 
insulin analogue only, in the first trimester compared 
with those exposed to human insulin. This decrease 
was driven by a reduction of risk for congenital heart 
defects. Studies outside pregnancy have showed that the 
use of insulin analogues has been associated with either 
modestly improved glycaemic control or fewer hypo-
glycaemic episodes.10 12 Recent data have emphasised 
the role of glucose stability in the pathogenesis of fetal 
malformations, as a single day of poor glycaemic control 
had potential for a negative impact on organogenesis.26 27 
It is possible that insulin analogues reduced the risk of 
congenital anomalies by achieving better glucose stability 
and consequently reduced glucose-level variation. 
We might speculate that patients treated with insulin 
analogues had less frequent very high glucose spikes or 
hypoglycaemic episodes that might be responsible for 
impaired fetal development in very early pregnancy. 
However, our study is lacking information on glucose 
variability, which may also be a confounding factor. 
Much remains to be learnt about the biological mech-
anisms that explain the observed association between 
insulin analogues and congenital anomalies and whether 
insulin analogues could reduce the risk of congenital 
heart defects. The rate of major congenital anomalies was 
8.0% in the reference group—exposure to the human 
insulin only. This rate is higher compared with the rate 
of congenital anomalies in the recent UK National Preg-
nancy and Diabetes Audit: 46.2 for type 1 diabetes and 
34.6 for type 2 diabetes per 1000 live births and still-
births.28 This suggests that hyperglycaemia might be more 
severe, more frequent or possibly due to less adherence 
to treatment among women with diabetes in the human 
insulin only group. This may have exacerbated the differ-
ence in insulin analogue and human insulin outcomes 
beyond purely treatment-related effects. Although we do 
not have a clear explanation for this higher rate, it calls 
for increased counselling efforts towards diabetic women 
of childbearing age.
In our data, pregnancies with exposure to insulin 
analogues had significantly higher rate of spontaneous 
abortion compared with exposure to human insulin, 
which has not been previously reported. When we 
combined the adverse outcomes, including fetal death 
and congenital anomaly, we did not see increased risks 
with insulin analogues compared with human insulin. 
There were two cases with severe congenital heart defects 
among fetuses exposed to human insulin only and 0 
cases of severe congenital heart defects in the insulin 
analogue only exposed group. These numbers are too 
small to interpret and formulate any conclusions. It is 
difficult to say which is worse scenario: the increased risk 
(if verified) of early-spontaneous abortion following expo-
sure to insulin analogues or the increased risk of septal 
defect, that often close spontaneously, following expo-
sure to human insulin only. There were no cases with the 
caudal regression sequence. We would not expect to have 
a case in our cohort of 1661 fetuses due to its low preva-
lence (1 per 50 000 births),29 although caudal regression 
sequence is highly associated with maternal diabetes with 
OR >20 compared with pregnancies without diabetes.6
Our study established a large, retrospective cohort 
of pregnancies with diabetes, with detailed informa-
tion on treatment of diabetes, HbA1c value and other 
exposure characteristics. The strength of this study is 
its use of multiple centres that represent geographically 
distinct areas where patterns of treatment of diabetes 
are different. Another strength of the study was the valid 
information on congenital anomaly gained by linking to 
the EUROCAT database and by reclassifying the cases with 
written text descriptions of a congenital anomaly based 
on EUROCAT subgroup definition. The EUROCAT data-
base includes well-validated, comparable and specific 
information on congenital anomalies in births as well as 
terminations of pregnancies. In addition, the associations 
between some well-known risk factors (such as HbA1c and 
planned pregnancy) and congenital anomalies in preg-
nancies with diabetes were consistent with prior reports, 
supporting the premise that the exposures and outcomes 
of interest were well captured in our study.
Our results should be interpreted in the context of 
limitations inherent in its design and local variations. We 
tried to identify potential confounders of the association 
between treatment of diabetes and subsequent congen-
ital anomalies, but it remains possible that residual bias 
is still present because of unmeasured or not perfectly 
measured or unknown confounders, for example, other 
as yet unknown differences between groups of insulin 
use. Our study is a retrospective cohort with informa-
tion based on medical records and healthcare data-
bases, which were not primarily designed for the current 
research purposes in most centres. Our data sources 
have incomplete data on HbA1c and pregnancy plan-
ning, which may represent a source of potential residual 
confounding. Fetuses of mothers with missing values of 
HbA1c had an increased risk of congenital anomalies/
congenital heart defects in our data. In the sensitivity 
analysis by including ‘missing HbA1c value’ in the model 
as a separate group, the risk estimation did not show a 
significant difference from the analysis that excluded 
missing HbA1c. We were not able to adjust for precon-
ception care (eg, screening and treatment of compli-
cations of diabetes, folic acid supplementation) which 
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is also known to lower the risk of congenital anomaly. 
In addition, it is possible that the underlying choice of 
insulin analogue, human insulin or the switch to insulin 
analogue may confound the risk estimation in the study. 
Information on the use of an insulin pump, which may 
have an important impact on the stability of glucose 
level control, is missing in our study. Pregnant women 
with renal disease might have a higher risk of congenital 
anomalies, but information on microvascular complica-
tions, particularly diabetic nephropathy is lacking. The 
cohort data were collected at centres for pregnancies 
with diabetes and the gestational age at referral to these 
centres may differ between regions. Therefore, the inclu-
sion of spontaneous abortions may differ. The low rate 
of spontaneous abortion in our study may be due to the 
medical records not starting very early in pregnancy; 
therefore, early spontaneous abortion may not have 
been captured in our database. Spontaneous abortion 
was not a primary outcome of the study. Ascertainments 
of congenital anomalies procedures vary between regis-
tries, although we adjusted for region in the analysis. 
The follow-up period for inclusion of congenital anom-
alies varies in the EUROCAT registries. As septal defects 
often are diagnosed after the neonatal period depending 
on the local protocol, there may be a difference in the 
inclusion of ASD and VSD. On the other hand, regions 
with frequent use of echocardiography in the neonatal 
units may diagnose more septal defects in the neonatal 
period.30 A further limitation of this analysis is the low 
number of exposed cases, and even though we applied 
methods appropriate for small cell counts, our ability to 
control confounding is limited. The absolute numbers 
of anomalies are small and may be a chance finding or 
explained by unadjusted confounders. While the biolog-
ical effect varies according to each type of insulin among 
short-acting or long-acting insulin analogues, the low 
numbers of anomalies limited our ability to evaluate the 
risk in relation to each individual analogue. Because the 
database did not contain information on lifestyle factors 
(eg, smoking, obesity, alcohol), we were not able to 
examine their potential for such confoundings.
In conclusion, our results suggest that first trimester 
use of insulin analogues does not increase the risk of 
a congenital anomaly among women with diabetes 
compared with the use of human insulin. This is the first 
study that shows a significantly lower risk of congenital 
heart defects in relation to insulin analogue use, but 
caution is warranted due to the small numbers of anom-
alies and the as yet unknown confounders. Our study 
provides a further piece of evidence on the relative safety 
of insulin analogues with regards to congenital anomaly, 
in particular to congenital heart defects. The relative 
higher proportion of spontaneous abortion among 
women exposed to insulin analogues observed in our 
study needs to be investigated in an independent dataset 
as it was not the primary outcome of our study.
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